Novartis: Glioblastoma trials
The registry lists 22 Glioblastoma studies with Novartis as lead sponsor. 0 are open to participants now and 8 have results posted.
Early Phase 1 1Phase 1 13Phase 2 10Phase 3 1Phase 4 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid TumorsTerminatedNCT02829723Phase 1/2Results posted
- Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG TumorsCompletedNCT02684058Phase 2Results posted
- Ceritinib Rare Indications Study in ALK+ TumorsTerminatedNCT02465528Phase 2Results posted
- A Phase 2 Study of BGJ398 in Patients With Recurrent GBMCompletedNCT01975701Phase 2Results posted
- Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent GlioblastomaTerminatedNCT01870726Phase 1/2Results posted
- Study of Everolimus (RAD001) in Patients With Recurrent Glioblastoma Multiforme (GBM)TerminatedNCT00515086Phase 2Results posted
- Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM)TerminatedNCT00290771Phase 2Results posted
- Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive GlioblastomaCompletedNCT00154375Phase 3Results posted
- A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors.TerminatedNCT05977322Phase 1
- Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent GlioblastomaActive, not recruitingNCT05739942Phase 1
- A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.Active, not recruitingNCT05109728Phase 1
- Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins.TerminatedNCT04712721Early Phase 1
- Pediatric Long-Term Follow-up and Rollover StudyActive, not recruitingNCT03975829Phase 4
- A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 MutationsActive, not recruitingNCT02381886Phase 1
- Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma MultiformeCompletedNCT01934361Phase 1
- Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid TumorsCompletedNCT01576666Phase 1
- A Phase I Dose Escalation Study of BKM120 With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed GlioblastomaCompletedNCT01473901Phase 1
- Study of INC280 in Patients With c-MET Dependent Advanced Solid TumorsCompletedNCT01324479Phase 1
- Open-label Trial of Imatinib Mesylate in Patients With Unresectable Recurrent Glioblastoma Multiforme Expressing PDGFR (Platelet Derived Growth Factor Receptors)TerminatedNCT00171938Phase 2
- Study of AEE788 in Patients With Recurrent/Relapse Glioblastoma Multiforme (GBM)CompletedNCT00116376Phase 1/2
- AEE788 and Everolimus in Treating Patients With Recurrent or Relapsed Glioblastoma MultiformeCompletedNCT00107237Phase 1/2
- Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent CancerCompletedNCT00006368Phase 1